Lynch Syndrome is the most common form of hereditary colorectal cancer.
By implementing Lynch syndrome pathways nationally for both colorectal and endometrial cancer there is the opportunity to detect many of these at an earlier stage and also prevent cancers through risk reduction treatments and appropriate surveillance routes.
Guidance on management of Lynch syndrome published by NHS UK (July 2021).
Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen (PSA) screening from age 40 to identify men with clinically significant prostate cancer, according to the initial results of the IMPACT study (NCT00261456) that were published in TheLancet Oncology.1
“A patient can have the most thorough and accurate genetic testing available, but if that information is not integrated into their health care, that testing is meaningless. Or worse, if that testing is not interpreted correctly, it can be harmful”
Conclusions:Familial burden – in addition to age, sex, and specific LS gene – should be used to assess LS carriers’ risks of specific cancers and guide decision-making about organ-specific surveillance.